{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:18:53Z","timestamp":1793312333530,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017531","name":"Medical and Health Research Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022KY069"],"award-info":[{"award-number":["2022KY069"]}],"id":[{"id":"10.13039\/501100017531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017531","name":"Medical and Health Research Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2021KY040"],"award-info":[{"award-number":["2021KY040"]}],"id":[{"id":"10.13039\/501100017531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005199","name":"Chinese Medicine Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2021ZZ001"],"award-info":[{"award-number":["2021ZZ001"]}],"id":[{"id":"10.13039\/501100005199","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005199","name":"Chinese Medicine Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2022ZB017"],"award-info":[{"award-number":["2022ZB017"]}],"id":[{"id":"10.13039\/501100005199","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jpba.2023.115937","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T03:44:16Z","timestamp":1703303056000},"page":"115937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":115,"special_numbering":"C","title":["Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS\/MS and its application in the clinical determination in patients with tumors associated with overactive bladder"],"prefix":"10.1016","volume":"240","author":[{"given":"Yutao","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kening","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihua","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115937_bib1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2147\/IJWH.S369588","article-title":"Adherence to overactive bladder syndrome treatments recent developments and future perspectives","volume":"15","author":"Robinson","year":"2023","journal-title":"Int. J. Women\u2019s. Health"},{"key":"10.1016\/j.jpba.2023.115937_bib2","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/nau.25221","article-title":"One treatment with onabotulinumtoxinA relieves symptoms of overactive bladder in patients refractory to one or more oral medications","volume":"42","author":"Farrelly","year":"2023","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.jpba.2023.115937_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/TCRM.S269318","article-title":"Assessing quality-of-life of patients taking mirabegron for overactive bladder","volume":"19","author":"Shaw","year":"2023","journal-title":"Ther. Clin. Risk. Manag."},{"key":"10.1016\/j.jpba.2023.115937_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.eururo.2013.08.031","article-title":"Global prevalence and economic burden of urgency urinary incontinence: a systematic review","volume":"65","author":"Milsom","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jpba.2023.115937_bib5","article-title":"Efficacy and safety of mirabegron in the treatment of overactive bladder syndrome after radical prostatectomy: a prospective randomized controlled study","volume":"13","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jpba.2023.115937_bib6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2023.05.014","volume":"84","author":"Farag","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jpba.2023.115937_bib7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/UPJ.0000000000000243","article-title":"Yearly trends of overactive bladder medication usage","volume":"8","author":"Chua","year":"2021","journal-title":"Urol. Pract."},{"key":"10.1016\/j.jpba.2023.115937_bib8","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40265-013-0086-3","article-title":"Mirabegron: a review of its use in patients with overactive bladder syndrome","volume":"73","author":"Sanford","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2023.115937_bib9","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40273-022-01163-5","article-title":"Budget impact analysis of vibegron for the treatment of overactive bladder in the USA","volume":"40","author":"Chen","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jpba.2023.115937_bib10","article-title":"Inhibition of prejunctional parasympathetic pathways by \u03b23-adrenoceptor agonists in the isolated pig detrusor: comparison with human detrusor studies","volume":"14","author":"D'Agostino","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jpba.2023.115937_bib11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00345-016-1908-1","volume":"35","author":"Abrams","year":"2017","journal-title":"World J. Urol."},{"key":"10.1016\/j.jpba.2023.115937_bib12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.116.237313","article-title":"Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder","volume":"360","author":"Di Salvo","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2023.115937_bib13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1080\/14656566.2022.2126311","article-title":"Vibegron for the treatment of overactive bladder: a comprehensive update","volume":"23","author":"Gleicher","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jpba.2023.115937_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14656566.2020.1809652","article-title":"Evaluating vibegron for the treatment of overactive bladder","volume":"22","author":"Rechberger","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jpba.2023.115937_bib15","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.jpba.2023.115937_bib16","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/nau.24732","article-title":"Cardiovascular safety of vibegron, a new \u03b23-adrenoceptor agonist, in older patients with overactive bladder: post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study","volume":"40","author":"Yoshida","year":"2021","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.jpba.2023.115937_bib17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jchromb.2012.01.018","article-title":"Development and validation of LC-MS\/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study","volume":"887-888","author":"Teijlingen","year":"2012","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2023.115937_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpba.2019.02.007","article-title":"Validation of LC-MS\/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population","volume":"167","author":"Meijer","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115937_bib19","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.clinthera.2012.09.010","article-title":"Pharmacokinetic properties of mirabegron, a \u03b23-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women","volume":"34","author":"Krauwinkel","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jpba.2023.115937_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1590\/1806-9282.65.2.141","article-title":"Determination of Mirabegron in rat plasma by UPLC-MS\/MS after oral and intravenous administration","volume":"65","author":"Chen","year":"2019","journal-title":"Rev. Assoc. Med. Bras."},{"key":"10.1016\/j.jpba.2023.115937_bib21","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cpdd.1169","article-title":"Pharmacokinetics and safety of vibegron 75 mg administered as an intact or crushed tablet in healthy adults","volume":"11","author":"King","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523007069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523007069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:06:48Z","timestamp":1777572408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523007069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":21,"alternative-id":["S0731708523007069"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115937","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS\/MS and its application in the clinical determination in patients with tumors associated with overactive bladder","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115937","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115937"}}